Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity
Blood biomarkers are needed for behavioral variant frontotemporal dementia (bvFTD).Plasma hexosylceramides are reduced in bvFTD cases compared with normal controls.Plasma hexosylceramides correlate with disease duration in bvFTD.Plasma hexosylceramides correlate with brain white matter integrity in bvFTD.Plasma glycolipids have potential as biomarkers of disease progression in bvFTD.
Authors
- Ramón Landín-Romero (ORCID: https://orcid.org/0000-0003-0485-8090)
- John B. Kwok (ORCID: https://orcid.org/0000-0001-9574-6195)
- Anthony S. Don (ORCID: https://orcid.org/0000-0003-1655-1184)
- Woojin Scott Kim (ORCID: https://orcid.org/0000-0002-4707-933X)
- Carol Dobson‐Stone (ORCID: https://orcid.org/0000-0002-2211-0257)
- Glenda Margaret Halliday (ORCID: https://orcid.org/0000-0003-0422-8398)
- Olivier Piguet (ORCID: https://orcid.org/0000-0002-6696-1440)
- Oana C. Marian (ORCID: https://orcid.org/0000-0001-5629-7884)
- Sophie Matis (ORCID: https://orcid.org/0009-0005-1458-2181)
Institutions
- The University of Sydney (AU)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/dad2.70131
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- University of Sydney
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council